PolyPid Ltd
NASDAQ:PYPD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PolyPid Ltd
Net Issuance of Common Stock
PolyPid Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Net Issuance of Common Stock
$32.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Net Issuance of Common Stock
$6k
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-81%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Net Issuance of Common Stock
$31m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
100%
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PolyPid Ltd
Glance View
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
See Also
What is PolyPid Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
32.6m
USD
Based on the financial report for Dec 31, 2025, PolyPid Ltd's Net Issuance of Common Stock amounts to 32.6m USD.
What is PolyPid Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-12%
Over the last year, the Net Issuance of Common Stock growth was -9%. The average annual Net Issuance of Common Stock growth rates for PolyPid Ltd have been -20% over the past three years , -12% over the past five years .
